The Protective Role of PAC1-Receptor Agonist Maxadilan in BCCAO-Induced Retinal Degeneration

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2016 Aug 28

PMID 27566170

Citations 18

Authors

A Vaczy

D Reglodi

T Somoskeoy

K Kovacs

E Lokos

E Szabo

A Tamas

T Atlasz

Affiliations

Soon will be listed here.

Abstract

A number of studies have proven that pituitary adenylate cyclase activating polypeptide (PACAP) is protective in neurodegenerative diseases. Permanent bilateral common carotid artery occlusion (BCCAO) causes severe degeneration in the rat retina. In our previous studies, protective effects were observed with PACAP1-38, PACAP1-27, and VIP but not with their related peptides, glucagon, or secretin in BCCAO. All three PACAP receptors (PAC1, VPAC1, VPAC2) appear in the retina. Molecular and immunohistochemical analysis demonstrated that the retinoprotective effects are most probably mainly mediated by the PAC1 receptor. The aim of the present study was to investigate the retinoprotective effects of a selective PAC1-receptor agonist maxadilan in BCCAO-induced retinopathy. Wistar rats were used in the experiment. After performing BCCAO, the right eye was treated with intravitreal maxadilan (0.1 or 1 μM), while the left eye was injected with vehicle. Sham-operated rats received the same treatment. Two weeks after the operation, retinas were processed for standard morphometric and molecular analysis. Intravitreal injection of 0.1 or 1 μM maxadilan caused significant protection in the thickness of most retinal layers and the number of cells in the GCL compared to the BCCAO-operated eyes. In addition, 1 μM maxadilan application was more effective than 0.1 μM maxadilan treatment in the ONL, INL, IPL, and the entire retina (OLM-ILM). Maxadilan treatment significantly decreased cytokine expression (CINC-1, IL-1α, and L-selectin) in ischemia. In summary, our histological and molecular analysis showed that maxadilan, a selective PAC1 receptor agonist, has a protective role in BCCAO-induced retinal degeneration, further supporting the role of PAC1 receptor conveying the retinoprotective effects of PACAP.

Citing Articles

Optimization of an Ischemic Retinopathy Mouse Model and the Consequences of Hypoxia in a Time-Dependent Manner.

Bosnyak I, Farkas N, Molitor D, Meresz B, Patko E, Atlasz T Int J Mol Sci. 2024; 25(15).

PMID: 39125579 PMC: 11311598. DOI: 10.3390/ijms25158008.

Protective Effects of Pituitary Adenylate-Cyclase-Activating Polypeptide on Retinal Vasculature and Molecular Responses in a Rat Model of Moderate Glaucoma.

Patko E, Szabo E, Vaczy A, Molitor D, Tari E, Li L Int J Mol Sci. 2023; 24(17).

PMID: 37686074 PMC: 10487862. DOI: 10.3390/ijms241713256.

Downregulation of PACAP and the PAC1 Receptor in the Basal Ganglia, Substantia Nigra and Centrally Projecting Edinger-Westphal Nucleus in the Rotenone model of Parkinson's Disease.

Feher M, Marton Z, Szabo A, Kocsa J, Kormos V, Hunyady A Int J Mol Sci. 2023; 24(14).

PMID: 37511603 PMC: 10380602. DOI: 10.3390/ijms241411843.

Relevance of Peptide Homeostasis in Metabolic Retinal Degenerative Disorders: Curative Potential in Genetically Modified Mice.

Postyeni E, Ganczer A, Kovacs-Valasek A, Gabriel R Front Pharmacol. 2022; 12:808315.

PMID: 35095518 PMC: 8793341. DOI: 10.3389/fphar.2021.808315.

Retinoprotective Effects of PACAP Eye Drops in Microbead-Induced Glaucoma Model in Rats.

Szabo E, Patko E, Vaczy A, Molitor D, Csutak A, Toth G Int J Mol Sci. 2021; 22(16).

PMID: 34445531 PMC: 8396165. DOI: 10.3390/ijms22168825.

References

Babai N, Atlasz T, Tamas A, Reglodi D, Toth G, Kiss P . Search for the optimal monosodium glutamate treatment schedule to study the neuroprotective effects of PACAP in the retina. Ann N Y Acad Sci. 2006; 1070:149-55. DOI: 10.1196/annals.1317.003. View

Tuncel N, Basmak H, Uzuner K, Tuncel M, Altiokka G, Zaimoglu V . Protection of rat retina from ischemia-reperfusion injury by vasoactive intestinal peptide (VIP): the effect of VIP on lipid peroxidation and antioxidant enzyme activity of retina and choroid. Ann N Y Acad Sci. 1996; 805:489-98. DOI: 10.1111/j.1749-6632.1996.tb17509.x. View

Chapter M, White C, DeRidder A, Chadwick W, Martin B, Maudsley S . Chemical modification of class II G protein-coupled receptor ligands: frontiers in the development of peptide analogs as neuroendocrine pharmacological therapies. Pharmacol Ther. 2009; 125(1):39-54. PMC: 2815023. DOI: 10.1016/j.pharmthera.2009.07.006. View

Padua D, Vu J, Germano P, Pisegna J . The Role of Neuropeptides in Mouse Models of Colitis. J Mol Neurosci. 2015; 59(2):203-10. PMC: 4884658. DOI: 10.1007/s12031-015-0688-1. View

Vollmar B, Menger M . Intestinal ischemia/reperfusion: microcirculatory pathology and functional consequences. Langenbecks Arch Surg. 2010; 396(1):13-29. DOI: 10.1007/s00423-010-0727-x. View

Harmar A, Sheward W, Morrison C, Waser B, Gugger M, Reubi J . Distribution of the VPAC2 receptor in peripheral tissues of the mouse. Endocrinology. 2003; 145(3):1203-10. DOI: 10.1210/en.2003-1058. View

Hoover D, Tompkins J, Parsons R . Differential activation of guinea pig intrinsic cardiac neurons by the PAC1 agonists maxadilan and pituitary adenylate cyclase-activating polypeptide 27 (PACAP27). J Pharmacol Exp Ther. 2009; 331(1):197-203. PMC: 2766232. DOI: 10.1124/jpet.109.155747. View

Krajcs N, Hernadi L, Pirger Z, Reglodi D, Toth G, Kiss T . PACAP Modulates Acetylcholine-Elicited Contractions at Nicotinic Neuromuscular Contacts of the Land Snail. J Mol Neurosci. 2015; 57(4):492-500. DOI: 10.1007/s12031-015-0605-7. View

Scuderi S, DAmico A, Castorina A, Imbesi R, Carnazza M, DAgata V . Ameliorative effect of PACAP and VIP against increased permeability in a model of outer blood retinal barrier dysfunction. Peptides. 2012; 39:119-24. DOI: 10.1016/j.peptides.2012.11.015. View

10.

Moro O, Wakita K, Ohnuma M, Denda S, Lerner E, Tajima M . Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. J Biol Chem. 1999; 274(33):23103-10. DOI: 10.1074/jbc.274.33.23103. View

11.

Toker E, Kazokoglu H, Sahin S . Cell adhesion molecules in subretinal fluid: soluble forms of VCAM-1 (vascular cell adhesion molecule-1) and L-selectin. Int Ophthalmol. 1999; 22(2):71-6. DOI: 10.1023/a:1006160209657. View

12.

Shioda S, Takenoya F, Wada N, Hirabayashi T, Seki T, Nakamachi T . Pleiotropic and retinoprotective functions of PACAP. Anat Sci Int. 2016; 91(4):313-24. DOI: 10.1007/s12565-016-0351-0. View

13.

Ohnou T, Yokai M, Kurihara T, Hasegawa-Moriyama M, Shimizu T, Inoue K . Pituitary adenylate cyclase-activating polypeptide type 1 receptor signaling evokes long-lasting nociceptive behaviors through the activation of spinal astrocytes in mice. J Pharmacol Sci. 2016; 130(4):194-203. DOI: 10.1016/j.jphs.2016.01.008. View

14.

Juhasz T, Helgadottir S, Tamas A, Reglodi D, Zakany R . PACAP and VIP signaling in chondrogenesis and osteogenesis. Peptides. 2015; 66:51-7. DOI: 10.1016/j.peptides.2015.02.001. View

15.

Kanekar S, Gandham M, Lucero M . PACAP protects against TNFα-induced cell death in olfactory epithelium and olfactory placodal cell lines. Mol Cell Neurosci. 2010; 45(4):345-54. PMC: 2962708. DOI: 10.1016/j.mcn.2010.07.007. View

16.

Atlasz T, Szabadfi K, Kiss P, Tamas A, Toth G, Reglodi D . Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res Bull. 2009; 81(4-5):497-504. DOI: 10.1016/j.brainresbull.2009.09.004. View

17.

Seki T, Izumi S, Shioda S, Zhou C, Arimura A, Koide R . Gene expression for PACAP receptor mRNA in the rat retina by in situ hybridization and in situ RT-PCR. Ann N Y Acad Sci. 2001; 921:366-9. DOI: 10.1111/j.1749-6632.2000.tb06995.x. View

18.

Jander S, Sitzer M, Schumann R, Schroeter M, Siebler M, Steinmetz H . Inflammation in high-grade carotid stenosis: a possible role for macrophages and T cells in plaque destabilization. Stroke. 1998; 29(8):1625-30. DOI: 10.1161/01.str.29.8.1625. View

19.

Szabadfi K, Atlasz T, Kiss P, Danyadi B, Tamas A, Helyes Z . Mice deficient in pituitary adenylate cyclase activating polypeptide (PACAP) are more susceptible to retinal ischemic injury in vivo. Neurotox Res. 2011; 21(1):41-8. DOI: 10.1007/s12640-011-9254-y. View

20.

Dinarello C . Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011; 117(14):3720-32. PMC: 3083294. DOI: 10.1182/blood-2010-07-273417. View